Abiopharma

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

PacBio Announces Third Quarter 2025 Financial Results

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Rhythm Pharmaceuticals annonce le remboursement public de lIMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

HealthEquity Announces Third Quarter Earnings Date